Figure 1
From: The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
In endothelial cells, after activation, VEGFR2 is able to stimulate the AKT/mTOR signalling pathway through PI3K. More downstream 4E-BP1, P70S6K1 and S6 are phosphorylated. The mTORC2 complex (insensitive to rapamycin/FKBP12) has been shown to be an activator of AKT. The mTORC1 complex is sensitive to rapamycin (sirolimus) or derivates (everolimus, temsirolimus and deforolimus).
